FAQ: Improving CML Therapy
Improving Outcomes for Patients With CML With TKIs: FAQ Podcast

Released: August 13, 2020

Expiration: August 12, 2021

Carlo Gambacorti-Passerini
Carlo Gambacorti-Passerini, MD

Activity

Progress
1
Course Completed

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:

  • Frontline Management of Chronic-Phase CML
  • Selection of TKI Based on Goal of Treatment-Free Remission
  • Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
  • Changing TKIs due to CML Progression: Second-line Therapy and Future Options 

Content based on an online CME program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/improving-cml-outcomes